AVEO Pharma stock rises 6% after cancer drug gets approved
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer08/29/2017
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Urology & Nephrology